Clinical Trials for Bladder Cancer

201411135

Tissue, Blood, and Urine Acquisition for Molecular and Cellular Analysis and Collection of Health Information for Patients with Malignancies of the Genitourinary Tract Phase N/A Principal Investigator Pachynski, Russell Disease Site Kidney; Other Endocrine System;…

201510089

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological…

201711182

A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer Phase III Principal…

201712042

A Multicenter Study to Explore the Mechanism of Acquired Immune Escape in Patients with Metastatic Cancer Progressing on Checkpoint Inhibitor Therapy Phase IV Principal Investigator Pachynski, Russell Disease Site Anus; Bones and Joints; Brain and…

201807022

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma Phase II Principal Investigator Picus, Joel Disease Site Urinary Bladder Learn more about this study at: clinicaltrials.gov

201809005

A phase II study of dose-dense gemcitabine plus cisplatin (ddGC) in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations Phase II Principal…

201811079

A Randomized Phase II Study of Atezolizumab (MPDL3280A) plus Recombinant Human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma Phase II Principal Investigator Pachynski, Russell Disease Site Other Urinary; Urinary Bladder Learn…

201910162

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer Phase III Principal Investigator Baumann, Brian Disease Site Urinary Bladder Learn more about this study at: clinicaltrials.gov

202003048

A Phase 3, Randomized, Double-Blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) Phase III Principal…

202005122

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors Phase I/II Principal Investigator Ward, Jeffrey Disease Site Breast; Cervix; Corpus Uteri; Ill-Defined Sites; Lip, Oral Cavity…

202007149

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer Phase I/II (Cancer Control) Principal Investigator Picus, Joel Disease Site Urinary Bladder Learn more…

202102193

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial Phase III Principal Investigator Reimers, Melissa Disease Site Other Urinary; Urinary Bladder Learn more about this study…